$90m IPO Sets Up Sweden's Calliditas For Phase III Readout

Biotech Sector Listings Defying Pandemic

 
• By Andrew McConaghie
  
Going public
The Nasdaq IPO gears the company up for a US commercial focus

More from Business

More from Scrip